4D MOLECULAR THERAPEUTICS INC. - COMMON STOCK

4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer

13 апр 2023 08:00:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights

15 мар 2023 16:05:01 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™

22 фев 2023 16:05:00 Источник Nasdaq GlobeNewswire

4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™

16 фев 2023 16:05:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference

08 фев 2023 16:05:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema

02 фев 2023 16:05:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference

21 ноя 2022 16:05:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)

14 ноя 2022 07:30:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022

10 ноя 2022 16:05:01 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results

09 ноя 2022 16:05:02 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022

03 ноя 2022 09:45:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022

26 окт 2022 16:05:01 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer

27 сен 2022 16:10:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

20 сен 2022 16:15:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update

11 авг 2022 16:03:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Upcoming June Investor Conferences

02 июн 2022 16:02:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

12 май 2022 16:01:01 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference

05 май 2022 16:02:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis

04 апр 2022 16:02:00 Источник Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights

28 мар 2022 16:02:00 Источник Nasdaq GlobeNewswire